Core Viewpoint - The company, Puris, has established itself as a leader in the SMO (Site Management Organization) industry since 2009, benefiting from the growth in clinical trial demand, industry concentration, and the empowerment of intelligent technology, which is expected to drive sustained growth in the medium to long term [3]. Industry Overview - The SMO industry is experiencing rapid development, driven by increasing investment in innovative drug research and a steady rise in the number of clinical trials. The annual registration of drug clinical trials in China is projected to reach 4,900 in 2024, representing a year-on-year growth of 13.9%. The domestic clinical trial volume is expected to maintain a compound annual growth rate of 15-20% over the next 3-5 years, providing continuous growth momentum for the SMO industry [3]. - The market share of leading companies in the SMO sector is anticipated to further concentrate, with the top five players holding approximately 25-30% of the market share as of 2021, according to ZhiShi Consulting [3]. Company Strengths - The company has built significant competitive advantages through its extensive project experience, systematic quality control capabilities, and a nationwide execution network. The company has undertaken over 4,200 projects, demonstrating strong capabilities in complex fields, particularly in oncology [4][6]. - The quality control system of the company is well-established, earning trust from clients and showcasing excellent performance in past project audits. The company has strong brand recognition and customer loyalty, securing partnerships with top global pharmaceutical companies such as Pfizer, Roche, and Johnson & Johnson [6]. - The company has a robust workforce of 4,271 employees, ensuring reliability and stability in clinical trial execution, with coverage across more than 200 cities and 960 institutions [6]. Financial Projections - The company is expected to achieve net profits of 119 million, 160 million, and 198 million yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 12.2%, 33.7%, and 24.4%. The earnings per share (EPS) are projected to be 1.51, 2.02, and 2.51 yuan for the same years [4]. - The current stock price corresponds to price-to-earnings (PE) ratios of 46, 35, and 28 for the years 2025 to 2027. Given the company's clear growth potential and significant competitive advantages, a target price of 93 yuan is set based on a 46x PE for 2026, with an initial recommendation of "Buy" [4].